NurExone https://nurexone.com/ From acute injury to functional recovery Sun, 26 Oct 2025 07:48:47 +0000 en-US hourly 1 https://wordpress.org/?v=6.8.3 https://nurexone.com/wp-content/uploads/2024/02/NurExone-Logo-Rebrand-icon-copy-150x150.webp NurExone https://nurexone.com/ 32 32 Developing Exosome-Based RNA Therapeutics For CNS Regeneration https://nurexone.com/developing-exosome-based-rna-therapeutics-for-cns-regeneration/ https://nurexone.com/developing-exosome-based-rna-therapeutics-for-cns-regeneration/#respond Sun, 26 Oct 2025 07:46:48 +0000 https://nurexone.com/developing-exosome-based-rna-therapeutics-for-cns-regeneration/ As exosomes have emerged as a next-generation therapeutic platform for multiple diseases, leaders in the RNA community are now focusing on these nanoparticles as the ultimate drug delivery system for a wide range of indications from oncology to dermatology. NurExone has taken a unique approach and is using exosome therapies for regenerative medicine to develop […]

The post Developing Exosome-Based RNA Therapeutics For CNS Regeneration appeared first on NurExone.

]]>
As exosomes have emerged as a next-generation therapeutic platform for multiple diseases, leaders in the RNA community are now focusing on these nanoparticles as the ultimate drug delivery system for a wide range of indications from oncology to dermatology. NurExone has taken a unique approach and is using exosome therapies for regenerative medicine to develop promising therapies for central nervous system (CNS) injury. In this Q&A, Advancing RNA’s Acquisition Editor Michael Soloway caught up with NurExone Biologic’s CEO, Lior Shaltiel, Ph.D., to discuss the company’s approach to RNA therapeutics.

READ MORE >>>

The post Developing Exosome-Based RNA Therapeutics For CNS Regeneration appeared first on NurExone.

]]>
https://nurexone.com/developing-exosome-based-rna-therapeutics-for-cns-regeneration/feed/ 0
BioProcess Europe https://nurexone.com/bioprocess-europe/ https://nurexone.com/bioprocess-europe/#respond Fri, 24 Oct 2025 13:10:27 +0000 https://nurexone.com/where-innovation-meets-implementation-experience-europes-new-era-of-therapeutic-manufacturing/ The post BioProcess Europe appeared first on NurExone.

]]>
The post BioProcess Europe appeared first on NurExone.

]]>
https://nurexone.com/bioprocess-europe/feed/ 0
NanoIL 2026 https://nurexone.com/nanoil-2026/ https://nurexone.com/nanoil-2026/#respond Fri, 24 Oct 2025 13:06:24 +0000 https://nurexone.com/nanoil-2026/ The post NanoIL 2026 appeared first on NurExone.

]]>
The post NanoIL 2026 appeared first on NurExone.

]]>
https://nurexone.com/nanoil-2026/feed/ 0
הכנס השנתי למחקר וניסויים קליניים https://nurexone.com/%d7%94%d7%9b%d7%a0%d7%a1-%d7%94%d7%a9%d7%a0%d7%aa%d7%99-%d7%9c%d7%9e%d7%97%d7%a7%d7%a8-%d7%95%d7%a0%d7%99%d7%a1%d7%95%d7%99%d7%99%d7%9d-%d7%a7%d7%9c%d7%99%d7%a0%d7%99%d7%99%d7%9d-2/ https://nurexone.com/%d7%94%d7%9b%d7%a0%d7%a1-%d7%94%d7%a9%d7%a0%d7%aa%d7%99-%d7%9c%d7%9e%d7%97%d7%a7%d7%a8-%d7%95%d7%a0%d7%99%d7%a1%d7%95%d7%99%d7%99%d7%9d-%d7%a7%d7%9c%d7%99%d7%a0%d7%99%d7%99%d7%9d-2/#respond Fri, 24 Oct 2025 12:54:36 +0000 https://nurexone.com/%d7%94%d7%9b%d7%a0%d7%a1-%d7%94%d7%a9%d7%a0%d7%aa%d7%99-%d7%9c%d7%9e%d7%97%d7%a7%d7%a8-%d7%95%d7%a0%d7%99%d7%a1%d7%95%d7%99%d7%99%d7%9d-%d7%a7%d7%9c%d7%99%d7%a0%d7%99%d7%99%d7%9d-2/ The post הכנס השנתי למחקר וניסויים קליניים appeared first on NurExone.

]]>
The post הכנס השנתי למחקר וניסויים קליניים appeared first on NurExone.

]]>
https://nurexone.com/%d7%94%d7%9b%d7%a0%d7%a1-%d7%94%d7%a9%d7%a0%d7%aa%d7%99-%d7%9c%d7%9e%d7%97%d7%a7%d7%a8-%d7%95%d7%a0%d7%99%d7%a1%d7%95%d7%99%d7%99%d7%9d-%d7%a7%d7%9c%d7%99%d7%a0%d7%99%d7%99%d7%9d-2/feed/ 0
NurExone Invited Presenter at Precision EV Forum in Cambridge, UK https://nurexone.com/nurexone-invited-presenter-at-precision-ev-forum-in-cambridge-uk/ https://nurexone.com/nurexone-invited-presenter-at-precision-ev-forum-in-cambridge-uk/#respond Tue, 21 Oct 2025 11:54:34 +0000 https://nurexone.com/nurexone-invited-presenter-at-precision-ev-forum-in-cambridge-uk/ TORONTO and HAIFA, Israel, Oct. 21, 2025 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) a biopharmaceutical company developing exosome-based regenerative therapies, announced that Dr. Ina Sarel, Director of Clinical and Regulatory Affairs, has been invited to speak at the Precision EV Forum 2025, being held October 27–28 […]

The post NurExone Invited Presenter at Precision EV Forum in Cambridge, UK appeared first on NurExone.

]]>
TORONTO and HAIFA, Israel, Oct. 21, 2025 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) a biopharmaceutical company developing exosome-based regenerative therapies, announced that Dr. Ina Sarel, Director of Clinical and Regulatory Affairs, has been invited to speak at the Precision EV Forum 2025, being held October 27–28 in Cambridge, UK. Her participation underscores growing global recognition of NurExone’s leadership in developing exosome therapies and in helping define the regulatory path for this emerging field.

Dr. Sarel will present “Regulatory Challenges in the Clinical Development of ExoPTEN: MSC EVs Loaded with PTEN-siRNA” on October 28, followed by a panel discussion on how developers of exosome therapeutics can better approach regulatory approval. The invitation reflects strong international interest in NurExone’s lead program, ExoPTEN, a drug under development that combines regenerative and anti-inflammatory mechanisms to repair Central Nervous System damage.

Read More >>>

The post NurExone Invited Presenter at Precision EV Forum in Cambridge, UK appeared first on NurExone.

]]>
https://nurexone.com/nurexone-invited-presenter-at-precision-ev-forum-in-cambridge-uk/feed/ 0
Exosome Exotherapy: Lior Shaltiel on a Platform for CNS Regeneration https://nurexone.com/exosome-exotherapy-lior-shaltiel-on-a-platform-for-cns-regeneration/ https://nurexone.com/exosome-exotherapy-lior-shaltiel-on-a-platform-for-cns-regeneration/#respond Thu, 16 Oct 2025 12:01:18 +0000 https://nurexone.com/exosome-exotherapy-lior-shaltiel-on-a-platform-for-cns-regeneration/ Today, we sit down with Dr. Lior Shaltiel of NurExone Biologics to explore how exosome-based delivery of siRNA could redefine CNS repair. We discuss why exosomes might overcome safety and manufacturing hurdles that hampered cell therapies, how early preclinical signals are guiding a rigorous first-in-human path, how endpoints and patient realities shape trial design, and […]

The post Exosome Exotherapy: Lior Shaltiel on a Platform for CNS Regeneration appeared first on NurExone.

]]>
Today, we sit down with Dr. Lior Shaltiel of NurExone Biologics to explore how exosome-based delivery of siRNA could redefine CNS repair. We discuss why exosomes might overcome safety and manufacturing hurdles that hampered cell therapies, how early preclinical signals are guiding a rigorous first-in-human path, how endpoints and patient realities shape trial design, and the broader potential of exotherapy as a platform for regenerative medicine. This conversation highlights leadership in translating promising science into a practical regulatory and business strategy amid a challenging funding climate.

 

Read More >>>

The post Exosome Exotherapy: Lior Shaltiel on a Platform for CNS Regeneration appeared first on NurExone.

]]>
https://nurexone.com/exosome-exotherapy-lior-shaltiel-on-a-platform-for-cns-regeneration/feed/ 0
NurExone Demonstrates Reproducible, Dose-Dependent Vision Recovery in Preclinical Glaucoma Model https://nurexone.com/nurexone-demonstrates-reproducible-dose-dependent-vision-recovery-in-preclinical-glaucoma-model/ https://nurexone.com/nurexone-demonstrates-reproducible-dose-dependent-vision-recovery-in-preclinical-glaucoma-model/#respond Wed, 08 Oct 2025 06:40:58 +0000 https://nurexone.com/nurexone-demonstrates-reproducible-dose-dependent-vision-recovery-in-preclinical-glaucoma-model/ TORONTO and HAIFA, Israel, Oct. 08, 2025 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) a biopharmaceutical company developing exosome-based regenerative therapies, announced new preclinical results showing that its lead candidate ExoPTEN produces a reproducible, dose-dependent therapeutic effect in an eye model of glaucoma. The study was conducted […]

The post NurExone Demonstrates Reproducible, Dose-Dependent Vision Recovery in Preclinical Glaucoma Model appeared first on NurExone.

]]>
TORONTO and HAIFA, Israel, Oct. 08, 2025 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) a biopharmaceutical company developing exosome-based regenerative therapies, announced new preclinical results showing that its lead candidate ExoPTEN produces a reproducible, dose-dependent therapeutic effect in an eye model of glaucoma.

The study was conducted in collaboration with Prof. Ygal Rotenstreich team at the Goldschleger Eye Institute at Sheba Medical Center, one of the world’s leading hospitalsi. It demonstrated that ExoPTEN’s biological activity increases with higher dosing levels in animals with optic nerve injury, resulting in consistent and measurable recovery of visual function. The findings show that ExoPTEN’s regenerative effect is reproducible, quantifiable, and scales with dose.

“Reproducibility is the key challenge in science, and now we have a first validation of the results,” said Prof. Michael Belkin, Professor Emeritus of Ophthalmology at Tel Aviv University and Scientific Advisor to NurExone. “These results confirm that ExoPTEN has the potential impact of a true therapeutic, producing reproducible repair of damaged optic nerves in small animals, advancing our ability to address vision loss in patients with optic nerve damage, such as glaucoma and related conditions.”

READ MORE >>>

The post NurExone Demonstrates Reproducible, Dose-Dependent Vision Recovery in Preclinical Glaucoma Model appeared first on NurExone.

]]>
https://nurexone.com/nurexone-demonstrates-reproducible-dose-dependent-vision-recovery-in-preclinical-glaucoma-model/feed/ 0
NurExone Planning to Establish First U.S. Commercial Manufacturing Facility in Indiana https://nurexone.com/nurexone-planning-to-establish-first-u-s-commercial-manufacturing-facility-in-indiana/ https://nurexone.com/nurexone-planning-to-establish-first-u-s-commercial-manufacturing-facility-in-indiana/#respond Wed, 17 Sep 2025 12:57:58 +0000 https://nurexone.com/nurexone-planning-to-establish-first-u-s-commercial-manufacturing-facility-in-indiana/ TORONTO and HAIFA, Israel and INDIANAPOLIS, Sept. 16, 2025 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical innovator in exosome-based regenerative therapies, is pleased to announce that its U.S. subsidiary, Exo-Top Inc. (“Exo-Top”), is planning to establish its first U.S. commercial exosome production facility in […]

The post NurExone Planning to Establish First U.S. Commercial Manufacturing Facility in Indiana appeared first on NurExone.

]]>
TORONTO and HAIFA, Israel and INDIANAPOLIS, Sept. 16, 2025 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical innovator in exosome-based regenerative therapies, is pleased to announce that its U.S. subsidiary, Exo-Top Inc. (“Exo-Top”), is planning to establish its first U.S. commercial exosome production facility in Indianapolis, Indiana.

The Indianapolis facility would serve as Exo-Top’s U.S. manufacturing base, transferring NurExone’s proprietary exosome production process into the American market. The GMP compliant site would produce exosomes both for NurExone’s therapeutic pipeline and for a growing business-to-business opportunity in regenerative aesthetics.

“Indiana’s commitment to building its life sciences cluster, outstanding logistics and strong incentives offer make Indianapolis the ideal home for Exo-Top, and we are honored to consider expanding into Indiana with the support of the Indiana Office of Commerce,” said Jacob Licht, CEO of Exo-Top. “By joining this ecosystem, we would contribute to Indiana’s biomanufacturing growth while securing a U.S. foundation for our therapeutic and commercial programs.”

READ MORE >>>

The post NurExone Planning to Establish First U.S. Commercial Manufacturing Facility in Indiana appeared first on NurExone.

]]>
https://nurexone.com/nurexone-planning-to-establish-first-u-s-commercial-manufacturing-facility-in-indiana/feed/ 0
NurExone Biologic Announces Corporate Updates including Israel Patent Grant and Private Placement Closing https://nurexone.com/nurexone-biologic-announces-corporate-updates-including-israel-patent-grant-and-private-placement-closing/ https://nurexone.com/nurexone-biologic-announces-corporate-updates-including-israel-patent-grant-and-private-placement-closing/#respond Thu, 11 Sep 2025 18:00:08 +0000 https://nurexone.com/nurexone-biologic-announces-corporate-updates-including-israel-patent-grant-and-private-placement-closing/ Israeli Patent Grant Expands Global Jurisdiction The Israel Patent Office has granted the Company’s Patent, entitled “Production of Extracellular Vesicles from Stem Cells.” This grant aligns with NurExone’s recently announced U.S. Notice of Allowance for the same priority family of applications. “While our clinical and commercial manufacturing of exosomes will be based in the U.S. […]

The post NurExone Biologic Announces Corporate Updates including Israel Patent Grant and Private Placement Closing appeared first on NurExone.

]]>
Israeli Patent Grant Expands Global Jurisdiction

The Israel Patent Office has granted the Company’s Patent, entitled “Production of Extracellular Vesicles from Stem Cells.” This grant aligns with NurExone’s recently announced U.S. Notice of Allowance for the same priority family of applications.

“While our clinical and commercial manufacturing of exosomes will be based in the U.S. through our Exo-Top Inc. subsidiary, expanding jurisdictional coverage further strengthens NurExone’s international intellectual property portfolio,” said Dr. Lior Shaltiel, CEO of NurExone.

Read More >>>

The post NurExone Biologic Announces Corporate Updates including Israel Patent Grant and Private Placement Closing appeared first on NurExone.

]]>
https://nurexone.com/nurexone-biologic-announces-corporate-updates-including-israel-patent-grant-and-private-placement-closing/feed/ 0
NurExone Receives U.S. Patent Allowance for Exosome Manufacturing, Strengthening Supply Chain Readiness https://nurexone.com/nurexone-receives-u-s-patent-allowance-for-exosome-manufacturing-strengthening-supply-chain-readiness/ https://nurexone.com/nurexone-receives-u-s-patent-allowance-for-exosome-manufacturing-strengthening-supply-chain-readiness/#respond Tue, 09 Sep 2025 14:45:00 +0000 https://nurexone.com/nurexone-receives-u-s-patent-allowance-for-exosome-manufacturing-strengthening-supply-chain-readiness/ TORONTO and HAIFA, Israel, Sept. 08, 2025 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a pioneering biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce that the United States Patent and Trademark Office has issued a Notice of Allowance for a patent covering the Company’s […]

The post NurExone Receives U.S. Patent Allowance for Exosome Manufacturing, Strengthening Supply Chain Readiness appeared first on NurExone.

]]>
TORONTO and HAIFA, Israel, Sept. 08, 2025 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a pioneering biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce that the United States Patent and Trademark Office has issued a Notice of Allowance for a patent covering the Company’s proprietary process for producing exosomes, natural cell-free nanoparticles derived from stem cells. The patent is part of an extensive international patent family, securing broad global protection and strengthening the company’s worldwide market position.

“This U.S. patent allowance secures long-term protection for our proprietary manufacturing process,” said Dr. Lior Shaltiel, Chief Executive Officer of NurExone. “With patent coverage in place and the recent acquisition of a Good Manufacturing Practice (“GMP”)-grade Master Cell Bank, we have reinforced the core elements of our supply chain. Combined with independent benchmarking that demonstrated the stronger regenerative potential of our exosomes, this milestone strengthens our path towards first-in-human trials and future commercial positioning.”

Prof. Shulamit Levenberg, lead inventor and NurExone Scientific Advisor, added: “This technology, which originated in my lab at the Technion, represents a unique and scalable method of manufacturing stem-cell derived exosomes. The allowance of this patent validates years of research and ensures that NurExone retains lasting intellectual property as it advances into clinical and commercial phases.”

READ MORE >>>

The post NurExone Receives U.S. Patent Allowance for Exosome Manufacturing, Strengthening Supply Chain Readiness appeared first on NurExone.

]]>
https://nurexone.com/nurexone-receives-u-s-patent-allowance-for-exosome-manufacturing-strengthening-supply-chain-readiness/feed/ 0